Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1978 2
1979 1
1981 1
1982 1
1984 1
1985 2
1986 2
1987 3
1988 5
1989 1
1990 3
1991 3
1993 2
1994 3
1995 4
1996 3
1997 3
1998 4
1999 2
2001 1
2002 4
2003 6
2004 3
2005 3
2007 1
2008 2
2009 5
2010 3
2011 3
2012 2
2014 2
2015 2
2016 3
2017 3
2018 3
2019 6
2020 6
2021 4
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Glanzmann thrombasthenia 2"
Page 1
Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
Di Minno G. Di Minno G. Blood Rev. 2015 Jun;29 Suppl 1:S26-33. doi: 10.1016/S0268-960X(15)30005-9. Blood Rev. 2015. PMID: 26073366 Review.
The frequency of these disorders in the general population ranges from 1:500,000 to 1:2,000,000. Because GT and FVII CD are both rare, registries are the only approach possible to allow the collection and analysis of sufficient observational data. ...This article su …
The frequency of these disorders in the general population ranges from 1:500,000 to 1:2,000,000. Because GT and FVII CD are both rare …
Antagonistic Roles of Human Platelet Integrin αIIbβ3 and Chemokines in Regulating Neutrophil Activation and Fate on Arterial Thrombi Under Flow.
Schönichen C, Montague SJ, Brouns SLN, Burston JJ, Cosemans JMEM, Jurk K, Kehrel BE, Koenen RR, Ní Áinle F, O'Donnell VB, Soehnlein O, Watson SP, Kuijpers MJE, Heemskerk JWM, Nagy M. Schönichen C, et al. Arterioscler Thromb Vasc Biol. 2023 Sep;43(9):1700-1712. doi: 10.1161/ATVBAHA.122.318767. Epub 2023 Jul 6. Arterioscler Thromb Vasc Biol. 2023. PMID: 37409530 Free PMC article.
The contributions of platelet-adhesive receptors (integrin, P-selectin, CD40L) and chemokines were studied by using inhibitors or antibodies and using blood from patients with GT (Glanzmann thrombasthenia) lacking platelet-expressed alphaIIbbeta3. RESULTS: We obs …
The contributions of platelet-adhesive receptors (integrin, P-selectin, CD40L) and chemokines were studied by using inhibitors or antibodies …
Molecular genetics aspects of factor XI deficiency and Glanzmann thrombasthenia.
Seligsohn U, Peretz H. Seligsohn U, et al. Haemostasis. 1994 Mar-Apr;24(2):81-5. doi: 10.1159/000217088. Haemostasis. 1994. PMID: 7959366 Review.
Factor XI deficiency and Glanzmann thrombasthenia are among the hereditary disorders frequently encountered in Israel. ...Preliminary data on factor XI intragenic polymorphic markers indeed indicate that type II and type III mutations reside on chromosomes each char …
Factor XI deficiency and Glanzmann thrombasthenia are among the hereditary disorders frequently encountered in Israel. ...Prel …
The use of prophylaxis in the treatment of rare bleeding disorders.
Shapiro A. Shapiro A. Thromb Res. 2020 Dec;196:590-602. doi: 10.1016/j.thromres.2019.07.014. Epub 2019 Jul 19. Thromb Res. 2020. PMID: 31420204 Review.
Rare bleeding disorders (RBDs) are a heterogeneous group of coagulation factor deficiencies that include fibrinogen, prothrombin, alpha(2)-antiplasmin, plasminogen activator inhibitor-1, and factors II, V, V/VIII, VII, X, XI and XIII. ...Platelet disorders including Gla …
Rare bleeding disorders (RBDs) are a heterogeneous group of coagulation factor deficiencies that include fibrinogen, prothrombin, alpha(2 …
A microchip flow-chamber assay screens congenital primary hemostasis disorders.
Nakajima Y, Yada K, Ogiwara K, Furukawa S, Shimonishi N, Shima M, Nogami K. Nakajima Y, et al. Pediatr Int. 2021 Feb;63(2):160-167. doi: 10.1111/ped.14378. Epub 2020 Dec 5. Pediatr Int. 2021. PMID: 32640065
We report the usefulness of a microchip flow-chamber system (T-TAS() ) for detecting and/or predicting clinical severity in patients with VWD type 1 and type 2N and platelet storage pool disease. ...METHODS: Microchips coated with collagen (PL-chip) and collagen/thrombopla …
We report the usefulness of a microchip flow-chamber system (T-TAS() ) for detecting and/or predicting clinical severity in patients …
Glanzmann Thrombasthenia: A Clinicopathological Profile.
Iqbal I, Farhan S, Ahmed N. Iqbal I, et al. J Coll Physicians Surg Pak. 2016 Aug;26(8):647-50. J Coll Physicians Surg Pak. 2016. PMID: 27539755
RESULTS: Among 796 patients, 163 (20.4%) patients were diagnosed with Glanzmann's thrombasthenia. The male to female ratio was 1.2:1. Their mean age was 7 2.5 years ranging from 3 months to 35 years. ...Platelet aggregation studies showed decreased agg …
RESULTS: Among 796 patients, 163 (20.4%) patients were diagnosed with Glanzmann's thrombasthenia. The male to female ratio was …
Identification of three novel pathogenic ITGA2B and one novel pathogenic ITGB3 mutations in patients with hereditary Glanzmann's thrombasthenia living in Eastern Turkey.
Karaman K, Yürektürk E, Geylan H, Yaşar AŞ, Karaman S, Aymelek HS, Çetin M, Oner AF. Karaman K, et al. Platelets. 2021 Feb 17;32(2):238-242. doi: 10.1080/09537104.2020.1732331. Epub 2020 Feb 22. Platelets. 2021. PMID: 32089034
Glanzmann's thrombasthenia (GT) is an autosomal recessive disorder in which the underlying problem is the lack or dysfunction of the GpIIb/IIIa receptor on the platelet surface. ...No association was found between the mutation type, and the bleeding scores an …
Glanzmann's thrombasthenia (GT) is an autosomal recessive disorder in which the underlying problem is the lack or dysfunction …
High-throughput elucidation of thrombus formation reveals sources of platelet function variability.
van Geffen JP, Brouns SLN, Batista J, McKinney H, Kempster C, Nagy M, Sivapalaratnam S, Baaten CCFMJ, Bourry N, Frontini M, Jurk K, Krause M, Pillitteri D, Swieringa F, Verdoold R, Cavill R, Kuijpers MJE, Ouwehand WH, Downes K, Heemskerk JWM. van Geffen JP, et al. Haematologica. 2019 Jun;104(6):1256-1267. doi: 10.3324/haematol.2018.198853. Epub 2018 Dec 13. Haematologica. 2019. PMID: 30545925 Free PMC article.
Microspots triggered platelet activation through GP Ib-V-IX, GPVI, CLEC-2 and integrins. For most thrombus parameters, inter-subject variation was 2-4 times higher than the intra-subject variation. ...Common sequence variation of GP6 and FCER1G, associated with GPVI …
Microspots triggered platelet activation through GP Ib-V-IX, GPVI, CLEC-2 and integrins. For most thrombus parameters, inter-subject …
Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb-IIIa: Is there a foetal risk?
Léticée N, Kaplan C, Lémery D. Léticée N, et al. Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):139-42. doi: 10.1016/j.ejogrb.2005.02.011. Eur J Obstet Gynecol Reprod Biol. 2005. PMID: 16054952 Review.
Isoantibody against GPIIb-IIIa complexes present on normal platelets can be observed in Glanzmann's thrombasthenia type I patients after platelet transfusion possibly leading to platelet transfusion refractoriness. Pregnancy in Glanzmann's thrombast …
Isoantibody against GPIIb-IIIa complexes present on normal platelets can be observed in Glanzmann's thrombasthenia type …
The necessity of repeat testing for von Willebrand disease in adult patients with mild to moderate bleeding disorders.
Mehic D, Kraemmer D, Tolios A, Bücheler J, Quehenberger P, Haslacher H, Ay C, Pabinger I, Gebhart J. Mehic D, et al. J Thromb Haemost. 2024 Jan;22(1):101-111. doi: 10.1016/j.jtha.2023.09.010. Epub 2023 Sep 21. J Thromb Haemost. 2024. PMID: 37741511
Using logistic regression, we estimated a probability of change of 26.4% (95% CI, 12.5-47.4) at baseline VWF levels of 30 IU/dL, 50.8% (95% CI, 35.6-65.8) at 50 IU/dL, 18.8% (95% CI, 12.3-27.6) at 60 IU/dL, and 1.2% (95% CI, 0.3-4.9) at 80 IU/dL. Baseline VWF was a strong …
Using logistic regression, we estimated a probability of change of 26.4% (95% CI, 12.5-47.4) at baseline VWF levels of 30 IU/dL, 50.8% (95% …
108 results